PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462912
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462912
Hematopoietic Stem Cell Transplantation Market size was valued at USD 2,823.12 Million in 2023, expanding at a CAGR of 10.7% from 2024 to 2032.
Many cancer forms and other illnesses can be treated with hematopoietic stem cell transplantation (HSCT). Two different sources of stem cells are bone marrow and blood. Hematopoietic stem cells are the young, immature blood cells found in bone marrow. The proportion of these blood cells that mature in the bone marrow and enter the bloodstream is quite low. The cells that reach the bloodstream are known as peripheral blood stem cells. After chemotherapy or radiation therapy, healthy hematopoietic stem cells are transplanted to replace absent, sick, or damaged hematopoietic stem cells.
Hematopoietic Stem Cell Transplantation Market- Market Dynamics
Increasing cases of leukemia and lymphoma to propel market demand
The market for hematopoietic stem cell transplantation is predicted to rise more rapidly due to the increased incidence of leukemia and lymphoma. In the United States, leukemia, lymphoma, or myeloma diagnosed 176,200 times, and lymph leukemia and myeloma survived in 1,399,180 cases, according to the Leukemia and Lymphoma Society's 2019 report. The market for hematopoietic stem cell transplantation (HSCT) is expected to grow as a result of the increasing incidence rate.
Hematopoietic Stem Cell Transplantation Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.7% over the forecast period (2024-2032)
Based on transplant type segmentation, the Autologous segment is expected to hold the largest market share over the forecast period
Based on application segmentation, the Bone Marrow Stem Cell Transplant segment is expected to hold a significant market share over the projected period
Based on region, North America was the leading revenue generator in 2023
The Global Hematopoietic Stem Cell Transplantation Market is segmented based on Transplant Type Application, Indication, End User, Therapeutic Area, and Region.
Based on the transplant type, the Hematopoietic Stem Cell Transplantation market is segmented into Autologous, Allogeneic and Others. The Autologous segment is expected to hold the largest market share over the forecast period due to advancements in technology, increased prevalence of hematological disorders, and expanding applications of stem cell therapies.
Based on the application, the Hematopoietic Stem Cell Transplantation industry is bifurcated into Cord Stem Cell Transplant, Bone Marrow Stem Cell Transplant, Peripheral Stem Cell Transplant and Others. The Bone Marrow Stem Cell Transplant segment is expected to hold a significant market share over the projected period. The main indications for bone marrow stem cell transplantation include non-malignant bone marrow-affecting diseases and a variety of hematological malignancies. These could include lymphomas, myelodysplastic syndromes, aplastic anemia, acute and chronic leukemias, and specific hereditary illnesses that impact the generation of red blood cells.
Based on the indication, the market is bifurcated into Leukemia, Lymphoproliferative Disorders, Non-Malignant Disorders and Others.
Based on the distribution channel, the industry is bifurcated into Offline and Online.
Based on the end user, the Hematopoietic Stem Cell Transplantation market is bifurcated into Retail Pharmacy, Hospital Pharmacy and Specialty Clinics.
Hematopoietic Stem Cell Transplantation Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold the largest market share over the forecast period. The market in the North American area is primarily driven by factors such as the rising number of leukemia patients and increased governmental and private sector expenditure in research and development. For instance, statistics released in May 2022 by the Canadian Cancer Society indicates that 6,700 Canadians are anticipated to receive a leukemia diagnosis year 2022. Additionally, it stated that 2,700 women will receive a leukemia diagnosis, 1,300 of them will pass away, and 4,000 males will receive a leukemia diagnosis.
The key players in the market are Pfizer Inc., Akari Therapeutics, Plc, Otsuka America Pharmaceutical, Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Lonza, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Sanofi, FUJIFILM Holdings Corporation, bluebird bio, Inc., Pluristem Therapeutics Inc., Regen Biopharma Inc., Kiadis Pharma, Taiga Biotechnologies, Inc., CellGenix GmbH, Escape Therapeutics, Inc., Marker Therapeutics, Inc. and Talaris Therapeutics.
In May 2022, Priothera was granted approval by the US Food and Drug Administration to begin a Phase 2b/3 research using mocravimod in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
GLOBAL HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Pfizer Inc.
Akari Therapeutics, Plc
Otsuka America Pharmaceutical, Inc.
Merck KGaA
Takeda Pharmaceutical Company Limited
Lonza
GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc.
Sanofi
FUJIFILM Holdings Corporation
bluebird bio, Inc.
Pluristem Therapeutics Inc.
Regen Biopharma Inc.
Kiadis Pharma
Taiga Biotechnologies, Inc.
CellGenix GmbH
Escape Therapeutics, Inc.
Talaris Therapeutics
Marker Therapeutics, Inc.